Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma Immunotherapy Consortium Real World Experience

•We explored the impact of ALC on the survival outcomes of myeloma patients treated with commercial idecabtagene vicleucel.•We created a new ALC profile and included 3 groups: Normal pre-lymphodepletion (LD) ALC, low pre-LD ALC + percent reduction (%R) from pre-apheresis to pre-LD of <37.5 and low pre-LD ALC + %R ≥37.5.•Low pre-LD ALC with high %R from pre-apheresis to pre-LD was associated with inferior survival outcomes.